Most Read Articles
3 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 4 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, Yesterday

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.

Keto diet beneficial to infants with drug-resistant epilepsy

17 Jun 2020

Ketogenic diet is safe and useful for treating infants with drug-resistant epilepsy, a recent study suggests.

Researchers searched multiple online databases for studies that provided seizure frequency data for infants aged <2 years who received treatment with high-fat diet for ≥1 month. Thirty‐three studies were included in the meta-analysis, of which two were randomized controlled trials and the remainder were uncontrolled. Five of these studies involved exclusively infants, while 28 included infants as part of a wider cohort.

A total of 534 infants who had followed a ketogenic diet for ≥1 month were included, of which 208 were from cohorts including solely infants. Eight studies only involved those with infantile spasms or West syndrome, and most studies included patients with a range of epilepsy syndromes. Mean age at seizure onset was 4.1 months, and mean age at diet onset was 13.0 months. The mean number of failed antiepileptic drugs prior to starting ketogenic diet was 2.9.

According to pooled data from uncontrolled studies, 59 percent of infants achieved ≥50 percent seizure reduction and 33 percent achieved seizure freedom. Retention rates varied between 84 percent at 3 months and 27 percent at 24 months.

Commonly reported side effects were dyslipidaemia (12 percent), vomiting (6 percent), constipation (4 percent), gastroesophageal reflux (4 percent), and diarrhoea (4 percent).

All studies were categorized as low quality. This underscores a need for high‐quality randomized controlled trials to validate the effectiveness, safety, and tolerability of dietary treatment in this vulnerable age group.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
3 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 4 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, Yesterday

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.